Insider Buying: TearLab Corp Director Brock Wright Purchases 11,354 Shares of Stock (TEAR)
TearLab Corp (NASDAQ:TEAR) Director Brock Wright acquired 11,354 shares of TearLab Corp stock on the open market in a transaction dated Tuesday, August 19th. The stock was purchased at an average cost of $3.83 per share, for a total transaction of $43,485.82. Following the transaction, the director now directly owns 657,632 shares in the company, valued at approximately $2,518,731. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.
A number of analysts have recently weighed in on TEAR shares. Analysts at Canaccord Genuity cut their price target on shares of TearLab Corp from $10.00 to $8.00 in a research note on Friday, August 8th. Analysts at Feltl & Co. downgraded shares of TearLab Corp from a “strong-buy” rating to a “buy” rating in a research note on Friday, August 8th.
TearLab Corp (NASDAQ:TEAR) opened at 3.92 on Friday. TearLab Corp has a 52-week low of $3.30 and a 52-week high of $13.55. The stock has a 50-day moving average of $4.5 and a 200-day moving average of $5.43. The company’s market cap is $131.7 million.
TearLab Corp (NASDAQ:TEAR) last released its earnings data on Thursday, August 7th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by $0.01. The company had revenue of $9.20 million for the quarter, compared to the consensus estimate of $5.12 million. The company’s revenue for the quarter was up 53.3% on a year-over-year basis. On average, analysts predict that TearLab Corp will post $-0.67 earnings per share for the current fiscal year.
TearLab Corp. is an in-vitro diagnostic company. The Company is commercializing a tear testing platform, the TearLab Osmolarity System that enables eye care practitioners to test for sensitive and specific biomarkers using nanoliters of tear film at the point-of-care.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.